Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults

Clinics in Liver Disease

Volumn 20, Issue 2, 2016, Pages 313-324

  Marengo, Andrea ^a   Jouness, Ramy Ibrahim Kamal ^a   Bugianesi, Elisabetta ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Cirrhosis; Hepatocellular carcinoma; Obesity; Steatohepatitis; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

AGE DISTRIBUTION; BODY MASS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; HUMAN; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; LIVER CELL CARCINOMA; MEDICAL HISTORY; METABOLIC SYNDROME X; MORTALITY RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PREVALENCE; PROGNOSIS; REVIEW; SURVIVAL TIME; CARCINOMA, HEPATOCELLULAR; COMPLICATION; GENETICS; IDEAL BODY WEIGHT; LIVER CIRRHOSIS; LIVER NEOPLASMS; MORTALITY; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTOR;

CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HUMANS; IDEAL BODY WEIGHT; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 84951838384     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2015.10.010     Document Type: Review

References (50)

1. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
2. Bedossa P., Flip Pathology Consortium Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014, 60:565-575.
3. Brunt E.M., Kleiner D.E., Wilson L.A., et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011, 53:810-820.
4. Angulo P. The natural history of NAFLD. Non-alcoholic fatty liver disease: a practical guide 2013, 37-45. Wiley Blackwell Press, London. G.C. Farrell, A.J. McCullough, C.P. Day (Eds.).
5. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
6. Teli M.R., James O.F., Burt A.D., et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22:1714-1719.
7. Dam-Larsen S., Franzmann M., Andersen I.B., et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004, 53:750-755.
8. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
9. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
10. Söderberg C., Stål P., Askling J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010, 51:595-602.
11. Lee R.G. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989, 20:594-598.
12. Powell E.E., Cooksley W.G., Hanson R., et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990, 11:74-80.
13. Evans C.D., Oien K.A., MacSween R.N., et al. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury?. J Clin Pathol 2002, 55:689-692.
14. Hashimoto E., Yatsuji S., Kaneda H., et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res 2005, 33:72-76.
15. Sanyal A.J., Banas C., Sargeant C., et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006, 43:682-689.
16. Ascha M.S., Hanouneh I.A., Lopez R., et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010, 51:1972-1978.
17. Bhala N., Angulo P., van der Poorten D., et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011, 54:1208-1216.
18. Stepanova M., Rafiq N., Makhlouf H., et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2013, 58:3017-3023.
19. Younossi Z.M., Stepanova M., Rafiq N., et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011, 53:1874-1882.
20. Angulo P., Bugianesi E., Bjornsson E.S., et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013, 145:782-789.
21. Singh S., Allen A.M., Wang Z., et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015, 13:643-654.
22. McPherson S., Hardy T., Henderson E., et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J Hepatol 2015, 62:1148-1155.
23. Valenti L., Al-Serri A., Daly A.K., et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51:1209-1217.
24. Rotman Y., Koh C., Zmuda J.M., et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010, 52:894-903.
25. Speliotes E.K., Butler J.L., Palmer C.D., et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010, 52:904-912.
26. Valenti L., Alisi A., Galmozzi E., et al. I148M patatinlike phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010, 52:1274-1280.
27. Sookoian S., Pirola C.J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011, 53:1883-1894.
28. Hui J.M., Kench J.G., Chitturi S., et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003, 38:420-427.
29. Sanyal A., Poklepovic A., Moyneur E., et al. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010, 26:2183-2191.
30. Yatsuji S., Hashimoto E., Tobari M., et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009, 24:248-254.
31. Bugianesi E., Leone N., Vanni E., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123:134-140.
32. Marrero J.A., Fontana R.J., Su G.L., et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002, 36:1349-1354.
33. Regimbeau J.M., Colombat M., Mognol P., et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004, 10:S69-S73.
34. Yasui K., Hashimoto E., Komorizono Y., et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011, 9:428-433.
35. Mittal S., Sada Y.H., El-Serag H.B., et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015, 13:594-601.
36. Wong R.J., Cheung R., Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patient with hepatocellular carcinoma in the U.S. Hepatology 2014, 59:2188-2195.
37. Tateishi R., Okanoue T., Fujiwara N., et al. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol 2015, 50:350-360.
38. Paradis V., Zalinski S., Chelbi E., et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009, 49:851-859.
39. Dyson J., Jaques B., Chattopadyhay D., et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and multidisciplinary team. J Hepatol 2014, 60:110-117.
40. Leung C., Yeoh S.W., Patrick D., et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol 2015, 21:1189-1196.
41. Tokushige K., Hashimoto E., Horie Y., et al. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol 2011, 46:1230-1237.
42. Wong V.W., Chu W.C., Wong G.L., et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012, 61:409-415.
43. Das K., Das K., Mukherjee P.S., et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010, 51:1593-1602.
44. Kwon Y.M., Oh S.W., Hwang S.S., et al. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am J Gastroenterol 2012, 107:1852-1858.
45. Liu C.J. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol 2012, 27:1555-1560.
46. Wong V.W., Wong G.L., Yeung D.K., et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol 2015, 62:182-189.
47. Younossi Z.M., Stepanova M., Negro F., et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine 2012, 91:319-327.
48. Vos B., Moreno C., Nagy N., et al. Lean nonalcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. Acta Gastroenterol Belg 2011, 74:389-394.
49. Wong V.W., Vergniol J., Wong G.L., et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010, 51:454-462.
50. Dela Cruz A.C., Bugianesi E., George J., et al. Characteristics and long-term prognosis of lean patients with non-alcoholic fatty liver disease. Gastroenterology 2014, 146:S-909.